Roche to present new data in multiple sclerosis and neuromyelitis optica spectrum disorder at MSVirtual2020
New data further reinforce OCREVUS (ocrelizumab) as a highly effective treatment option offering a favourable and consistent benefit:risk profile, with high treatment persistence and adherence Initiation of Phase IIIb OCREVUS higher dose clinical trial programme and Phase IV study evaluating OCREVUS in minority populations Initiation of Phase III clinical trial programme for fenebrutinib, an investigational... Read more